Connect with us


Mydecine Releases 2021 Financials and Announces Capital Raise

The article Mydecine Releases 2021 Financials and Announces Capital Raise was originally published on Microdose.

We’re combining two announcements here….



This article was originally published by

The article Mydecine Releases 2021 Financials and Announces Capital Raise was originally published on Microdose.

We’re combining two announcements here. Today Mydecine released its 2021 financial results and announced that they’ve closed the first part (tranche) of a new capital raise, namely 3,527,337 common shares for gross proceeds of $333,333.35.

As we’ve covered many times in these pages, Mydecine is a long-time underdog favorite, perpetually teasing us with its potential. However, the market downturn and diminishing cash reserves have been a concern, which is why these financial results and news of (for now quite small) capital infusion are welcomed insights for investors waiting to see what will happen next for the firm.

See below for the financial results press release and here for news on the capital raise.



Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update


Mar 31, 2022  

MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval

Company Advances IP Portfolio With New Patent Applications Covering Novel Molecule Families

DENVER, March 31, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a business update for the fiscal year ended December 31, 2021.

“Last year, Mydecine made significant strides toward creating and commercializing new treatments for mental health and addiction disorders,” said CEO Josh Bartch. “The conditional IRB approval we received is yet another positive signal that we will continue to advance our Phase 2b smoking cessation study, and we will hopefully receive full FDA IND approval in the second quarter of this year. We have been working hard to reduce our expenses and increase our efficiencies to continue progressing our clinical trials and expand our IP portfolio. I’d like to personally thank our shareholders, board members and highly dedicated team for enabling Mydecine to reach these significant milestones, and we look forward to another successful year.”

“In addition to our clinical trials, our research and development team has been making significant progress in our drug development program,” said Chief Scientific Officer Rob Roscow. “Over the last year, our new chemical entity (NCE) program has produced multiple patents covering several second-generation novel molecules that we believe will offer significant improvements over classic psilocybin and MDMA. We’re using a modular development approach to our patent strategy, which gives us the flexibility to license, partner or develop our lead drug candidates from our multiple families of NCEs, all wholly owned by Mydecine.”


Highlights of the Business for the Full Year 2021

Clinical Research

  • Progressed Phase 2b smoking cessation study following a positive meeting with the Food and Drug Administration (FDA) to review Mydecine’s Investigational New Drug (IND) application. In Q2 2022, the company plans to file an IND and breakthrough status application and will begin patient recruitment upon receipt of FDA approval. The multi-site study’s lead investigator will be Johns Hopkins University
  • Agreed to supply MYCO-001 for Dr. Matthew Johnson’s multi-site NIDA grant-funded smoking cessation study. Johns Hopkins University, New York University, and the University of Alabama in Birmingham are the investigative sites conducting the research. The results from this study will support the safety profile of MYCO-001.
  • Signed a five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine, demonstrating the Company’s commitment to advancing psychedelic medicine by exploring multiple molecules and drugs for various indications.

Drug Development

  • Filed several provisional and full patent applications for novel molecules that outperform first-generation compounds in safety, efficacy, stability, dosing and side effects. This year, the Company intends to file a number of new composition of matter patents supporting its NCE program.
    • Patent applications include: novel MDMA analogs, improved psilocybin and other tryptamines (including a shorter duration with patch delivery), potentially heart-safe microdosing drugs, nanoemulsion technology, and technology patents covering the digital healthcare platform Mindleap.
  • Unveiled an Artificial Intelligence (AI) drug discovery program that enables rapid screening of billions of compounds and will encourage near-term patent filings for novel molecules. Completed a 5-HT2A serotonin receptor model for Mydecine’s AI program with the intention to build the entire family of serotonin receptors to test its novel molecules against.
  • Screened over 25 mushroom species, including various varieties of p. cubensis, and discovered and analyzed more than 40 unique compounds, with the majority appearing to be previously unreported.


  • Welcomed several new independent board members, including Gordon Neal, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale, who bring a wealth of experience in drug development, clinical trials and technology. The additions assist Mydecine in meeting anticipated capital markets initiatives for 2022.
  • Listed on the NEO exchange and submitted an application to list on the NASDAQ.
  • Completed the first international export of psilocybin mushrooms.
  • Announced that Mydecine’s exclusive dealer was identified as a licensed psilocybin and MDMA supplier in Canada, allowing them to supply active pharmaceutical ingredients through Health Canada’s Special Access Program, which enables healthcare providers to request specific drugs for patients who have not responded well to other treatments.
  • Successfully spun out the Company’s legacy cannabis assets to help satisfy certain requirements for a potential future uplisting.


Financial Results for the Fiscal Year 2021

Net Loss: The net loss attributable to common stockholders was $28.9 million, which consisted of $5.3 million loss from discontinued operations, for the fiscal year ended December 31, 2021, or a basic and diluted loss per share attributable to common stockholders of ($0.12). This is compared to a net loss attributable to common stockholders of $26.9 million, which consisted of $0.1 million loss from discontinued operations, for the fiscal year ended December 31, 2020, or a basic and diluted loss per share attributable to common stockholders of ($0.24).

Cash Position: The Company had $1.5 million in cash and cash equivalents as of December 31, 2021. Subsequent to the year end, the Company secured additional funding and is moving forward with clinical trials and projects to expand its IP portfolio.





As at,   December 31, 2021


  December 31, 2020


Current assets      
Cash   1,495,311   2,190,702  
Accounts receivable   3,856   27,746  
Inventory     47,262  
Sales tax receivable   201,060   13,734  
Prepaids and deposits   3,521,125   216,003  
Total current assets   5,221,352   2,495,447  
Non-current assets      
Prepaids and deposits   1,793,894    
Investment in joint venture     303,982  
Loan receivable, net     316,110  
Investment in associate     4,481,988  
Right-of-use asset   130,546   223,645  
Investment properties     1,418,345  
Property and equipment   434,910   291,614  
Total assets   7,580,702   9,531,131  
Current liabilities      
Accounts payable and accrued liabilities   1,587,238   1,187,486  
Convertible debentures, net     2,959,755  
Derivative liabilities   1,280,294   1,586,744  
Lease liability – current portion   79,728   69,329  
Total current liabilities   2,369,383   5,803,314  
Non-current liabilities      
Convertible debentures, net   4,354,302    
Lease liability   67,821   167,118  
Total liabilities   7,369,383   5,970,432  
Shareholders’ equity      
Share capital   107,349,388   85,298,435  
Contributed surplus   17,536,315   12,734,636  
Equity portion of convertible debentures   240,756   254,690  
Accumulated other comprehensive loss     (444,803 )
Deficit   (124,915,140 ) (94,282,259 )
Total shareholders’ equity   211,319   3,560,699  
Total liabilities and shareholders’ equity   7,580,702   9,531,131  





    For the years ended,
    December 31,


  December 31,


Sales   7,493   2,617  
Cost of goods sold      
Gross margin   7,493   2,617  
Finance cost   205,267   182,866  
Corporate development   3,401,645   2,259,956  
Depreciation   235,177   57,080  
Consulting fees   5,220,556   3,381,726  
Director and management fees   1,346,468   539,347  
Foreign exchange loss   355,671   111,251  
Insurance   511,501    
Office and miscellaneous   925,568   292,070  
Professional fees   2,216,950   934,135  
Regulatory and filing fees   349,777   201,818  
Research and development   3,960,232   1,290,548  
Salaries   1,424,012   17,584  
Share-based payments   3,099,743   2,487,509  
Total expenses   23,252,567   11,755,890  
Other income (expenses)      
Change in fair value of derivative liabilities   43,688   545,194  
Consideration paid in excess of net assets acquired from acquisition     (10,645,239 )
Impairment of goodwill and intangible assets     (5,031,967 )
Impairment of loan receivable   (382,902 )  
Other expenses     (24,025 )
Gain on settlement of debt   1,377   33,304  
Total other income (expenses)   (337,837 ) (15,122,733 )
Loss from continuing operations   (23,582,911 ) (26,876,006 )
Loss from discontinued operations   (5,314,488 ) (72,939 )
Net loss for the year   (28,897,399 ) (26,948,945 )
Foreign currency translation adjustment     (382 )
Net loss and comprehensive loss for the year   (28,897,399 ) (26,949,327 )
Net loss per share – Basic and diluted from continuing operations   (0.12 ) (0.24 )
Weighted average number of shares outstanding – Basic and diluted   234,086,043   113,714,260  


About Mydecine Innovations Group

Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology company developing innovative first- and-second-generation novel therapeutics for the treatment of mental health and addiction using world-class technology and drug development infrastructure. Mydecine was founded in 2020 to address a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Our global team is dedicated to efficiently developing new therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The Mydecine business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy, as well as other novel, non-psychedelic molecules with therapeutic potential. By collaborating with some of the world’s foremost authorities, Mydecine aims to responsibly fast-track the development of new medicines to provide patients suffering from mental health disorders with safe and more effective treatment options. Mydecine Innovations Group is headquartered in Denver, Colorado, USA, with international offices in Leiden, Netherlands.

Learn more at: and follow us on Twitter, LinkedIn, YouTube and Instagram

For more information, please contact:

Media Contact

Morgan Kervitsky, Director of Marketing

Investor Relations

Morgan Kervitsky, Director of Marketing

On behalf of the Board of Directors:

Joshua Bartch, Chief Executive Officer

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at or visit the Company’s website at


Read More